quisinostat + paclitaxel + carboplatin

Quisinostat + paclitaxel + carboplatin is a combination regimen utilizing **quisinostat**, a potent oral pan-histone deacetylase (HDAC) inhibitor, with **paclitaxel** (a microtubule stabilizer) and **carboplatin** (a platinum-based DNA-damaging agent), primarily investigated for recurrent, platinum-resistant ovarian cancer. Quisinostat acts by inhibiting HDAC enzymes, leading to increased acetylation of histones and non-histone proteins, thereby affecting gene expression, apoptosis, and tumor cell proliferation. Paclitaxel disrupts microtubule function, causing mitotic arrest and cell death, while carboplatin induces DNA crosslinks and damage, leading to apoptosis. The combination benefits from potential synergistic effects, particularly enhancing sensitivity to chemotherapy in resistant populations. The regimen has displayed promising efficacy and tolerability in phase II clinical studies in patients with platinum-resistant ovarian cancer[1][3][9].